[go: up one dir, main page]

WO2003099231A3 - Composes heteroaryle inhibant l'adhesion leucocytaire induite par des integrines alpha-4 - Google Patents

Composes heteroaryle inhibant l'adhesion leucocytaire induite par des integrines alpha-4 Download PDF

Info

Publication number
WO2003099231A3
WO2003099231A3 PCT/US2003/017150 US0317150W WO03099231A3 WO 2003099231 A3 WO2003099231 A3 WO 2003099231A3 US 0317150 W US0317150 W US 0317150W WO 03099231 A3 WO03099231 A3 WO 03099231A3
Authority
WO
WIPO (PCT)
Prior art keywords
compounds
leukocyte adhesion
integrins
alpha
adhesion mediated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2003/017150
Other languages
English (en)
Other versions
WO2003099231A2 (fr
Inventor
Andrei W Konradi
Christopher M Semko
Ying-Zi Xu
Frank Stappenbeck
Brian P Stupi
Jenifer Smith
Eugene D Thorsett
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Elan Pharmaceuticals LLC
Original Assignee
Elan Pharmaceuticals LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to AT03736768T priority Critical patent/ATE464298T1/de
Priority to US10/494,788 priority patent/US7335663B2/en
Priority to DE60332109T priority patent/DE60332109D1/de
Priority to AU2003237302A priority patent/AU2003237302B8/en
Priority to CA002480756A priority patent/CA2480756A1/fr
Priority to EA200401561A priority patent/EA008180B1/ru
Priority to EP03736768A priority patent/EP1507533B1/fr
Priority to MXPA04011657A priority patent/MXPA04011657A/es
Priority to JP2004506758A priority patent/JP4413135B2/ja
Application filed by Elan Pharmaceuticals LLC filed Critical Elan Pharmaceuticals LLC
Priority to NZ535723A priority patent/NZ535723A/en
Priority to BR0309619-0A priority patent/BR0309619A/pt
Publication of WO2003099231A2 publication Critical patent/WO2003099231A2/fr
Publication of WO2003099231A3 publication Critical patent/WO2003099231A3/fr
Priority to IL164323A priority patent/IL164323A/en
Anticipated expiration legal-status Critical
Priority to NO20045276A priority patent/NO20045276L/no
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/50—Three nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne des composés se liant aux intégrines alpha-4 étant, de préférence, VLA-4. Certains de ces composés inhibent également l'adhésion leucocytaire et, notamment, l'adhésion leucocytaire induite par des intégrines alpha-4 étant, de préférence VLA-4. De tels composés sont utiles dans le traitement de maladies inflammatoires chez un patient mammifère, par exemple un être humain. On peut citer parmi de telles maladies inflammatoires : l'asthme, la maladie d'Alzheimer, l'athérosclérose, la démence du SIDA, les diabètes, une maladie intestinale inflammatoire, la polyarthrite rhumatoïde, une greffe tissulaire, des métastases tumorales et l'ischémie myocardique. Les composés peuvent également être administrés pour le traitement de maladies inflammatoires cérébrales, telles que la sclérose en plaques.
PCT/US2003/017150 2002-05-24 2003-05-27 Composes heteroaryle inhibant l'adhesion leucocytaire induite par des integrines alpha-4 Ceased WO2003099231A2 (fr)

Priority Applications (13)

Application Number Priority Date Filing Date Title
JP2004506758A JP4413135B2 (ja) 2002-05-24 2003-05-27 α４インテグリンによって媒介される白血球接着を阻害するヘテロアリール化合物
DE60332109T DE60332109D1 (de) 2002-05-24 2003-05-27 Heteroaryl-verbindungen zur hemmung der durch alpha-4-integrine vermittelten leukozytenadhäsion
AU2003237302A AU2003237302B8 (en) 2002-05-24 2003-05-27 Heteroaryl compounds which inhibit leukocyte adhesion mediated by alpha-4 integrins
CA002480756A CA2480756A1 (fr) 2002-05-24 2003-05-27 Composes heteroaryle inhibant l'adhesion leucocytaire induite par des integrines alpha-4
EA200401561A EA008180B1 (ru) 2002-05-24 2003-05-27 ГЕТЕРОАРИЛЬНЫЕ СОЕДИНЕНИЯ, КОТОРЫЕ ИНГИБИРУЮТ ОПОСРЕДОВАННУЮ α-ИНТЕГРИНАМИ АДГЕЗИЮ ЛЕЙКОЦИТОВ
EP03736768A EP1507533B1 (fr) 2002-05-24 2003-05-27 Composes heteroaryle inhibant l'adhesion leucocytaire induite par des integrines alpha-4
MXPA04011657A MXPA04011657A (es) 2002-05-24 2003-05-27 Compuestos de heteroarilo que inhiben la adhesion de leucocitos mediada por integrinas (4.
AT03736768T ATE464298T1 (de) 2002-05-24 2003-05-27 Heteroaryl-verbindungen zur hemmung der durch alpha-4-integrine vermittelten leukozytenadhäsion
NZ535723A NZ535723A (en) 2002-05-24 2003-05-27 Heteroaryl compounds which inhibit leukocyte adhesion mediated by alpha-4 integrins
US10/494,788 US7335663B2 (en) 2002-05-24 2003-05-27 Heteroaryl compounds which inhibit leukocyte adhesion mediated by α4 integrins
BR0309619-0A BR0309619A (pt) 2002-05-24 2003-05-27 Compostos de heteroarila os quais inibem a adesão de leucócitos mediada por integrinas (alfa)4
IL164323A IL164323A (en) 2002-05-24 2004-09-28 Heteroaryl compounds which inhibit leukocyte adhesion mediated by alpha - 4 integrins
NO20045276A NO20045276L (no) 2002-05-24 2004-12-01 Heteroarylforbindelser som inhiberer leukocyttadhesjon formidlet ved alfa-4-integriner

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US38324402P 2002-05-24 2002-05-24
US60/383,244 2002-05-24

Publications (2)

Publication Number Publication Date
WO2003099231A2 WO2003099231A2 (fr) 2003-12-04
WO2003099231A3 true WO2003099231A3 (fr) 2004-01-22

Family

ID=29584533

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/017150 Ceased WO2003099231A2 (fr) 2002-05-24 2003-05-27 Composes heteroaryle inhibant l'adhesion leucocytaire induite par des integrines alpha-4

Country Status (17)

Country Link
US (2) US7008949B2 (fr)
EP (1) EP1507533B1 (fr)
JP (1) JP4413135B2 (fr)
CN (1) CN1311829C (fr)
AT (1) ATE464298T1 (fr)
AU (1) AU2003237302B8 (fr)
BR (1) BR0309619A (fr)
CA (1) CA2480756A1 (fr)
DE (1) DE60332109D1 (fr)
EA (1) EA008180B1 (fr)
IL (1) IL164323A (fr)
MX (1) MXPA04011657A (fr)
NO (1) NO20045276L (fr)
NZ (1) NZ535723A (fr)
TW (1) TW200307671A (fr)
WO (1) WO2003099231A2 (fr)
ZA (1) ZA200407944B (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7579466B2 (en) 2006-02-27 2009-08-25 Elan Pharmaceuticals, Inc. Pyrimidinyl sulfonamide compounds which inhibit leukocyte adhesion mediated by VLA-4

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR0007663A (pt) * 1999-01-22 2002-05-07 Elan Pharm Inc Derivados de acila para uso no tratamento de doenças relacionadas com o vla-4
WO2005000244A2 (fr) * 2003-06-25 2005-01-06 Elan Pharmaceuticals, Inc. Methodes et compositions de traitement de la polyarthrite rhumatoide
AU2005222074B2 (en) * 2004-03-10 2011-02-17 Merck Sharp & Dohme Corp. VLA-4 antagonists
AR050425A1 (es) * 2004-07-08 2006-10-25 Elan Pharm Inc Antagonistas multivalentes de vla-4 que comprende fracciones polimericas. composiciones farmaceuticas
CN101006097B (zh) * 2004-08-16 2012-07-11 默沙东公司 Vla-4拮抗剂
US7727996B2 (en) 2005-09-29 2010-06-01 Elan Pharmaceuticals, Inc. Carbamate compounds which inhibit leukocyte adhesion mediated by VLA-4
CA2624450C (fr) * 2005-09-29 2014-02-04 Elan Pharmaceuticals, Inc. Composes de pyrimidinyl amide qui inhibent l'adherence leucocytaire a mediation par vla-4
WO2007100770A2 (fr) * 2006-02-28 2007-09-07 Elan Pharmaceuticals, Inc. Méthodes pour traiter des maladies inflammatoires et auto-immunes avec du natalizumab
US8410115B2 (en) * 2006-02-28 2013-04-02 Elan Pharmaceuticals, Inc. Methods of treating inflammatory and autoimmune diseases with alpha-4 inhibitory compounds
RS20080391A (sr) 2006-03-03 2009-07-15 Elan Pharmaceuticals Inc., Postupci lečenja zapaljenskih i autoimunih bolesti natalizumabom
CA2708262A1 (fr) * 2007-12-07 2009-06-18 Elan Pharmaceuticals, Inc. Procedes et compositions pour traiter des tumeurs liquides
CN102459179A (zh) * 2009-04-27 2012-05-16 艾伦药物公司 α-4整联蛋白的吡啶酮拮抗剂
RS63744B1 (sr) 2010-01-11 2022-12-30 Biogen Ma Inc Test za antitela protiv jc virusa
US11287423B2 (en) 2010-01-11 2022-03-29 Biogen Ma Inc. Assay for JC virus antibodies
US8343706B2 (en) * 2010-01-25 2013-01-01 International Business Machines Corporation Fluorine-free fused ring heteroaromatic photoacid generators and resist compositions containing the same
ES2729945T3 (es) 2011-05-31 2019-11-07 Biogen Ma Inc Procedimiento para valorar el riesgo de LMP
HK1216546A1 (zh) 2013-05-28 2016-11-18 Biogen Ma Inc. 评估pml风险的方法
WO2019246455A1 (fr) 2018-06-20 2019-12-26 Progenity, Inc. Traitement d'une maladie du tractus gastro-intestinal par un inhibiteur de l'intégrine
DK3873884T3 (da) 2018-10-30 2025-02-17 Gilead Sciences Inc 3-(quinolin-8-yl)-1,4-dihydropyrido[3,4-d]pyrimidin-2,4-dion-derivater som alpha4beta7-integrinhæmmere til behandling af inflammatoriske sygdomme
PL3873605T3 (pl) 2018-10-30 2025-03-03 Gilead Sciences, Inc. Związki hamujące integrynę alfa4beta7
WO2020092394A1 (fr) 2018-10-30 2020-05-07 Gilead Sciences, Inc. Dérivés d'imidazopyridine utilisés en tant qu'inhibiteurs de l'intégrine alpha4bêta7
EP3873897B1 (fr) 2018-10-30 2024-08-14 Gilead Sciences, Inc. Dérivés de n-benzoyl-phénylalanine en tant qu'inhibiteurs d'integrin alpha4béta7 pour le traitement de maladies inflammatoires
CN111197057B (zh) * 2018-11-19 2024-04-19 中国科学院分子细胞科学卓越创新中心 调控免疫细胞迁移的组合物和方法
US11578069B2 (en) 2019-08-14 2023-02-14 Gilead Sciences, Inc. Compounds for inhibition of α4 β7 integrin

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0330506A2 (fr) * 1988-02-26 1989-08-30 Dana Farber Cancer Institute Protéines VLA

Family Cites Families (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2525656A1 (de) 1974-06-19 1976-01-15 Sandoz Ag Verfahren zur herstellung neuer heterocyclischer verbindungen
US4055636A (en) * 1974-11-08 1977-10-25 Mitsubishi Chemical Industries Ltd. N2 -alkoxynaphthalenesulfonyl-L-argininamides and the pharmaceutically acceptable salts thereof
US4055651A (en) * 1974-11-08 1977-10-25 Mitsubishi Chemical Industries Ltd. N2 -alkoxynaphthalenesulfonyl-L-argininamides and the pharmaceutically acceptable salts thereof
US4070457A (en) * 1974-11-08 1978-01-24 Mitsubishi Chemical Industries Ltd. N2 -naphthalenesulfonyl-L-argininamides and the pharmaceutically acceptable salts thereof
US4073914A (en) * 1974-11-08 1978-02-14 Mitsubishi Chemical Industries Limited N2 -naphthalenesulfonyl-L-argininamides and the pharmaceutically acceptable salts thereof
US4096255A (en) * 1974-11-08 1978-06-20 Mitsubishi Chemical Industries Limited N2 -naphthalenesulfonyl-L-argininamides, and pharmaceutical salts, compositions and methods
US4104392A (en) 1974-11-08 1978-08-01 Mitsubishi Chemical Industries Ltd. N2 -naphthalenesulfonyl-L-argininamides and the pharmaceutically acceptable salts thereof, and antithrombotic compositions and methods employing them
US4018915A (en) * 1976-01-05 1977-04-19 Mitsubishi Chemical Industries Ltd. N2 -alkoxynaphthalenesulfonyl-L-argininamides and the pharmaceutically acceptable salts thereof
US4046876A (en) 1974-11-08 1977-09-06 Mitsubishi Chemical Industries Limited N2 -alkoxynaphthalenesulfonyl-L-argininamides and the pharmaceutically acceptable salts thereof
US4041156A (en) * 1974-11-08 1977-08-09 Mitsubishi Chemical Industries Limited N2 -alkoxynaphthalenesulfonyl-L-argininamides and the pharmaceutically acceptable salts thereof
JPS5727454B2 (fr) 1975-02-21 1982-06-10
US4018913A (en) 1976-01-14 1977-04-19 Mitsubishi Chemical Industries Ltd. N2 -alkoxynaphthalenesulfonyl-L-argininamides and the pharmaceutically acceptable salts thereof
CA1102316A (fr) 1975-12-09 1981-06-02 Shosuke Okamoto Traduction non-disponible
US4036955A (en) 1976-07-22 1977-07-19 Mitsubishi Chemical Industries Ltd. N2 -naphthalenesulfonyl-L-argininamides and the pharmaceutically acceptable salts thereof
DE2742173A1 (de) * 1977-09-20 1979-03-29 Bayer Ag Phenoxy-pyridinyl(pyrimidinyl)-alkanole, verfahren zu ihrer herstellung sowie ihre verwendung als fungizide
US4235871A (en) * 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
IT1211096B (it) * 1981-08-20 1989-09-29 Lpb Ist Farm Pirimidine e s.triazinici adattivita' ipolipidemizzante.
US4672065A (en) * 1982-11-19 1987-06-09 Chevron Research Company N-substituted phenoxyacetamide fungicides
US4501728A (en) * 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
CA1218655A (fr) 1983-01-28 1987-03-03 Kathleen Biziere Procede de preparation de derives de pyridazine a action psychotrope
JPS59212480A (ja) 1983-05-17 1984-12-01 Nippon Soda Co Ltd ピリダジン誘導体及び除草剤
DE3322720A1 (de) 1983-06-24 1985-01-03 Chemische Werke Hüls AG, 4370 Marl Verwendung von in 2-stellung mit (substituierten) aminogruppen substituierten 4-dl-alkylester-(alpha)-alaninyl-6-chlor-s-triazinen als herbizide, insbesondere gegen flughafer
US4505910A (en) 1983-06-30 1985-03-19 American Home Products Corporation Amino-pyrimidine derivatives, compositions and use
NZ210669A (en) 1983-12-27 1988-05-30 Syntex Inc Benzoxazin-4-one derivatives and pharmaceutical compositions
PH22520A (en) * 1984-11-12 1988-10-17 Yamanouchi Pharma Co Ltd Heterocyclic compounds having 4-lover alkyl-3-hydroxy-2-lower alkyl phenoxy-lower alkylene-y-group, and process of producing them
US4959364A (en) 1985-02-04 1990-09-25 G. D. Searle & Co. Method of treating inflammation, allergy, asthma and proliferative skin disease using heterocyclic amides
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US4837028A (en) * 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
JPH0784424B2 (ja) 1987-04-15 1995-09-13 味の素株式会社 チロシン誘導体及びその用途
DE3904931A1 (de) 1989-02-17 1990-08-23 Bayer Ag Pyridyl-substituierte acrylsaeureester
US5030644A (en) * 1989-07-31 1991-07-09 Merck & Co., Inc. Imidazole compounds and their use as transglutaminase inhibitors
US5260210A (en) 1989-09-27 1993-11-09 Rubin Lee L Blood-brain barrier model
US4992439A (en) 1990-02-13 1991-02-12 Bristol-Myers Squibb Company Pyridazine carboxylic acids and esters
FR2679903B1 (fr) 1991-08-02 1993-12-03 Elf Sanofi Derives de la n-sulfonyl indoline portant une fonction amidique, leur preparation, les compositions pharmaceutiques en contenant.
NZ239846A (en) * 1990-09-27 1994-11-25 Merck & Co Inc Sulphonamide derivatives and pharmaceutical compositions thereof
DE4108029A1 (de) * 1991-03-13 1992-09-17 Bayer Ag Triazinyl-substituierte acrylsaeureester
WO1992016549A1 (fr) 1991-03-18 1992-10-01 Pentapharm Ag Derives de phenylalanine substitues en position para
IT1247509B (it) * 1991-04-19 1994-12-17 Univ Cagliari Composti di sintesi atti all'impiego nella terapia delle infezioni da rhinovirus
US5296486A (en) 1991-09-24 1994-03-22 Boehringer Ingelheim Pharmaceuticals, Inc. Leukotriene biosynthesis inhibitors
AU3420693A (en) 1991-12-24 1993-07-28 Fred Hutchinson Cancer Research Center Competitive inhibition of high-avidity alpha4-beta1 receptor using tripeptide ldv
US5679688A (en) * 1992-03-11 1997-10-21 Narhex Limited Quinaldoyl-amine derivatives of oxo-and hydroxy-substituted hydrocarbons
DE4227748A1 (de) 1992-08-21 1994-02-24 Bayer Ag Pyridyloxy-acrylsäureester
JP2848232B2 (ja) * 1993-02-19 1999-01-20 武田薬品工業株式会社 アルデヒド誘導体
US5770573A (en) * 1993-12-06 1998-06-23 Cytel Corporation CS-1 peptidomimetics, compositions and methods of using the same
TW574214B (en) * 1994-06-08 2004-02-01 Pfizer Corticotropin releasing factor antagonists
US5510332A (en) * 1994-07-07 1996-04-23 Texas Biotechnology Corporation Process to inhibit binding of the integrin α4 62 1 to VCAM-1 or fibronectin and linear peptides therefor
DE69530392D1 (de) 1994-07-11 2003-05-22 Athena Neurosciences Inc Inhibitoren der leukozytenadhäsion
US6306840B1 (en) 1995-01-23 2001-10-23 Biogen, Inc. Cell adhesion inhibitors
IL117659A (en) * 1995-04-13 2000-12-06 Dainippon Pharmaceutical Co Substituted 2-phenyl pyrimidino amino acetamide derivative process for preparing the same and a pharmaceutical composition containing same
NZ318926A (en) * 1995-08-30 1999-04-29 Searle & Co Alpha v beta 3 integrin (vitronectin) inhibitors or anatagonists derived from benzoic acid for treating diseases of cell adhesion
CA2186650A1 (fr) * 1995-09-29 1997-03-30 Kazuo Sato Derives de substitution en 13 de milbemycin-5-oxime; preparation et utilisation contre les insectes et d'autres parasites
DE19536891A1 (de) 1995-10-04 1997-04-10 Basf Ag Neue Aminosäurederivate, ihre Herstellung und Verwendung
DE19548709A1 (de) 1995-12-23 1997-07-03 Merck Patent Gmbh Tyrosinderivate
WO1997048726A1 (fr) 1996-06-21 1997-12-24 Takeda Chemical Industries, Ltd. Procede de production de peptides
WO1998000395A1 (fr) 1996-06-28 1998-01-08 Merck Patent Gmbh Derives de phenylalanine utilises comme inhibiteurs de l'integrine
DE19629817A1 (de) * 1996-07-24 1998-01-29 Hoechst Ag Neue Imino-Derivate als Inhibitoren der Knochenresorption und Vitronectinrezeptor-Antagonisten
DE19647381A1 (de) * 1996-11-15 1998-05-20 Hoechst Ag Neue Heterocyclen als Inhibitoren der Leukozytenadhäsion und VLA-4-Antagonisten
DE19647317A1 (de) 1996-11-15 1998-05-20 Hoechst Schering Agrevo Gmbh Substituierte Stickstoff-Heterocyclen, Verfahren zu ihrer Herstellung und ihre Verwendung als Schädlingsbekämpfungsmittel
ATE295346T1 (de) 1996-11-22 2005-05-15 Elan Pharm Inc N-(aryl/heteroarylacetyl)aminosäureester, diese enthaltende pharmazeutische zusammensetzungen und methoden zur inhibierung der beta- amyloidfreisetzung und/oder deren synthese unter verwendung dieser verbindungen
WO1998033783A1 (fr) 1997-02-04 1998-08-06 Versicor, Inc. Syntheses de banques combinatoires et de phases solides de 3,1-benzoxazine-4-ones
DE19713000A1 (de) 1997-03-27 1998-10-01 Merck Patent Gmbh Adhäsionsrezeptor-Antagonisten
CA2291778A1 (fr) 1997-05-29 1998-12-03 Merck & Co., Inc. Composes d'amide heterocycliques utilises en tant qu'inhibiteurs de l'adhesion cellulaire
JP2001517245A (ja) 1997-05-29 2001-10-02 メルク エンド カンパニー インコーポレーテッド 細胞接着阻害薬としてのビアリールアルカン酸類
CN1265670A (zh) 1997-07-31 2000-09-06 伊兰药品公司 抑制vla－4介导的白细胞粘附的二肽和相关的化合物
JP2001512136A (ja) 1997-07-31 2001-08-21 エラン・ファーマシューティカルズ・インコーポレーテッド Ｖｌａ−４により仲介される白血球接着を抑制する化合物
AR016133A1 (es) 1997-07-31 2001-06-20 Wyeth Corp Compuesto de carbamiloxi que inhiben la adhesion de leucocitos mediada por vla-4, compuestos que son prodrogas de dichos compuestos, composicionfarmaceutica, metodo para fijar vla-4 a una muestra biologica, metodo para el tratamiento de una condicion inflamatoria
IL133640A0 (en) 1997-07-31 2001-04-30 Elan Pharm Inc Substituted phenylalanine type compounds which inhibit leukocyte adhesion mediated by vla-4
JP3727536B2 (ja) 1997-08-22 2005-12-14 エフ．ホフマン−ラ ロシュ アーゲー Ｎ−アルカノイルフェニルアラニン誘導体
RU2220950C2 (ru) 1997-08-22 2004-01-10 Ф.Хоффманн-Ля Рош Аг N-алканоилфенилаланиновые производные
EE200000428A (et) 1998-01-23 2001-12-17 Novartis Ag VLA-4 antagonistid
US6329372B1 (en) 1998-01-27 2001-12-11 Celltech Therapeutics Limited Phenylalanine derivatives
NZ507292A (en) 1998-04-10 2003-12-19 G Heterocyclic glycyl beta-alanine derivatives useful as vitronectin antagonists
JP4949552B2 (ja) 1998-04-16 2012-06-13 エンサイシブ・フアーマシユーテイカルズ，インコーポレイテツド インテグリンのそれの受容体への結合を阻害するｎ，ｎ−ジ置換アミド
GB9821061D0 (en) 1998-09-28 1998-11-18 Celltech Therapeutics Ltd Chemical compounds
GB9825652D0 (en) 1998-11-23 1999-01-13 Celltech Therapeutics Ltd Chemical compounds
WO2000043372A1 (fr) * 1999-01-22 2000-07-27 Elan Pharmaceuticals, Inc. Derives d'acyle utiles pour traiter des affections associees a vla-4
BR0007663A (pt) 1999-01-22 2002-05-07 Elan Pharm Inc Derivados de acila para uso no tratamento de doenças relacionadas com o vla-4

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0330506A2 (fr) * 1988-02-26 1989-08-30 Dana Farber Cancer Institute Protéines VLA

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7579466B2 (en) 2006-02-27 2009-08-25 Elan Pharmaceuticals, Inc. Pyrimidinyl sulfonamide compounds which inhibit leukocyte adhesion mediated by VLA-4

Also Published As

Publication number Publication date
EP1507533B1 (fr) 2010-04-14
US7335663B2 (en) 2008-02-26
CA2480756A1 (fr) 2003-12-04
US7008949B2 (en) 2006-03-07
AU2003237302A1 (en) 2003-12-12
AU2003237302B8 (en) 2008-04-03
EP1507533A2 (fr) 2005-02-23
MXPA04011657A (es) 2005-08-18
NZ535723A (en) 2005-08-26
US20040142954A1 (en) 2004-07-22
CN1311829C (zh) 2007-04-25
WO2003099231A2 (fr) 2003-12-04
US20050130999A1 (en) 2005-06-16
EA008180B1 (ru) 2007-04-27
BR0309619A (pt) 2005-06-28
DE60332109D1 (de) 2010-05-27
IL164323A (en) 2010-02-17
JP4413135B2 (ja) 2010-02-10
CN1652789A (zh) 2005-08-10
EP1507533A4 (fr) 2007-05-23
NO20045276L (no) 2004-12-01
IL164323A0 (en) 2005-12-18
JP2005529155A (ja) 2005-09-29
ATE464298T1 (de) 2010-04-15
ZA200407944B (en) 2006-07-26
TW200307671A (en) 2003-12-16
AU2003237302B2 (en) 2008-03-06
EA200401561A1 (ru) 2005-06-30

Similar Documents

Publication Publication Date Title
WO2003099231A3 (fr) Composes heteroaryle inhibant l'adhesion leucocytaire induite par des integrines alpha-4
IL164225A0 (en) Heterocyclic compounds which inhibit leukocyte adhesion mediated by 4 integrins
CA2290745A1 (fr) Composes de carbamyloxy inhibant une adhesion de leucocytes regulee par vla-4
TW200603788A (en) Multivalent vla-4 antagonists comprising polymer moieties
MXPA01007335A (es) Derivados de acilo los cuales tratan trastornos relacionados con alfa4 beta1 integrina y cd49d/cd29 (vla-4).
WO2000043354A3 (fr) Composes inhibant l'adhesion leucocytaire provoquee par vla-4
IL190084A0 (en) Pyrimidinyl amide compounds which inhibit leukocyte adhesion mediated by vla-4
WO2002008203A3 (fr) Derives de 3-(heteroaryl)alanine inhibiteurs de l'adherence des leucocytes provoquee par vla-4
MY151045A (en) Pyrimidinyl sulfonamide compounds which inhibit leukocyte adhesion mediated by vla-4
NO20000451L (no) Forbindelser som inhiberer leukocyttadhesjon mediert av VLA-4
NO20000412L (no) Dipeptidforbindelser som inhiberer leukocytt-adhesjon mediert av VLA-4
NO20000452L (no) Sulfonylerte dipeptidforbindelser som inhiberer leukocyttadhesjon mediert av VLA-4
NO20000414L (no) Benzylforbindelser som inhiberer leukocytt adhesjon mediert av VLA-4
WO2000043371A3 (fr) Composes fusionnes cycliques heteroaryle et heteroaryle inhibant l'adhesion des leucocytes provoquees par vla-4
WO2002008201A3 (fr) Derives de l'acide beta-amino inhibiteurs de l'adhesion des leucocytes induite par vla-4
AU3246600A (en) Alpha-aminoacetic acid derivatives useful as alpha 4 beta 7 receptor antagonists
WO2000043413A3 (fr) Derives d'acide pyroglutamique et composes associes, inhibiteurs de l'adhesion leukocytaire a mediation de vla-4
ZA200803016B (en) Carbamate compounds which inhibit leukocyte adhesion mediated by VLA-4

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 1200401213

Country of ref document: VN

AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2004506758

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 1-2004-501540

Country of ref document: PH

WWE Wipo information: entry into national phase

Ref document number: 2003237302

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 535723

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 2004/07944

Country of ref document: ZA

Ref document number: 200407944

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: 2003736768

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2480756

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 01533/KOLNP/2004

Country of ref document: IN

Ref document number: 1533/KOLNP/2004

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 1020047018326

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 20038112582

Country of ref document: CN

WWE Wipo information: entry into national phase

Ref document number: PA/a/2004/011657

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 10494788

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 200401561

Country of ref document: EA

WWP Wipo information: published in national office

Ref document number: 2003736768

Country of ref document: EP

Ref document number: 1020047018326

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: 535723

Country of ref document: NZ

WWG Wipo information: grant in national office

Ref document number: 535723

Country of ref document: NZ